Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299779 | 0.75 | MEN1 (0.41) | MAPK14MAPTALDH1A1HSP90AA1MEN1 | |
| SCHEMBL4295118 | 0.74 | MAPK14 (0.39) | MAPK14KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5226163 | 0.70 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL3786268 | 0.68 | MGLL (0.61) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1065129 | 0.68 | MAPK14 (0.43) | MAPK14MAPTKDM4EALDH1A1HSP90AA1 | |
| SCHEMBL3530385 | 0.66 | MAPK14 (0.38) | MAPK14KDM4EALDH1A1 | |
| SCHEMBL6669570 | 0.66 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL4286311 | 0.64 | MAPK14 (0.59) | MAPK14MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL29506614 | 0.64 | MAPK14 (0.48) | MAPK14MAPTKDM4EALDH1A1HSP90AA1 | |
| SCHEMBL16824852 | 0.63 | MAPT (0.44) | MAPK14MAPTKDM4EALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759486-B2 | Substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090105478-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105478-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPT 1719/4885KDM4E 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.